Oregon Pharmacy Dispensing of Mifepristone
On January 3, 2023, the US Food and Drug Administration (FDA) revised its Mifepristone Risk Evaluation and Mitigation Strategies (REMS) Program to allow pharmacies to dispense mifepristone directly to patients in person or by mail if certified by the Mifepristone REMS Program. The prescription must come from a provider who is certified by the Mifepristone REMS Program and has completed a Prescriber Agreement Form. Additionally, the patient and prescriber must complete a Patient Agreement Form prior to use, and pharmacies must complete a Pharmacy Agreement Form to become certified under the REMS Program.
Mifepristone is currently the subject of a lawsuit in Texas seeking to remove the U.S. Food and Drug Administration approval of the drug. Separately, Washington state is leading a group of 17 states (including Oregon) and the District of Columbia in a lawsuit to preserve and expand access to Mifepristone. On April 13, 2023, Judge Thomas O. Rice of the U.S. District Court for the Eastern District of Washington issued an order affirming that access to mifepristone remains protected in Washington and the other states (including Oregon) that are involved in the lawsuit. This protection means that mifepristone can be prescribed up to 10 weeks' gestation by any certified provider. It can be obtained directly from a REMS-certified pharmacy, through the mail and may be prescribed via telehealth appointments. (Updated April 13, 2023)
FDA: Information about Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation
FDA: Questions and Answers on Mifepristone for Medical Termination of Pregnancy Through Ten Weeks Gestation
Mifepristone Tablets, 200 mg